section name header

Indications

REMS


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Exercise Extreme Caution in:

Adv. Reactions/Side Effects

CV: hypotension, chest pain

Derm: rash

F and E: hyperkalemia

GI: abdominal pain, diarrhea, nausea, vomiting

GU: renal impairment

MS: back pain, myalgia

Neuro: dizziness, fatigue, headache

Resp: cough, dyspnea

Misc: ANGIOEDEMA

Interactions

Drug-drug:

Availability

(Generic available)

Route/Dosage

Hypertension

Renal Impairment

Heart Failure

Renal Impairment

US Brand Names

Accupril

Action

  • Angiotensin-converting enzyme (ACE) inhibitors block the conversion of angiotensin I to the vasoconstrictor angiotensin II. ACE inhibitors also prevent the degradation of bradykinin and other vasodilatory prostaglandins. ACE inhibitors also plasma renin levels and aldosterone levels. Net result is systemic vasodilation.
Therapeutic effects:
  • Lowering of BP in patients with hypertension.
  • Decreased afterload and symptoms in patients with HF.

Classifications

Therapeutic Classification: antihypertensives

Pharmacologic Classification: ace inhibitors

Pharmacokinetics

Absorption: 60% absorbed following oral administration (high-fat meal may absorption).

Distribution: Widely distributed to tissues..

Protein Binding: 97%.

Metabolism/Excretion: Converted by the liver, GI mucosa, and tissue to quinaprilat, the active metabolite: 96% eliminated by the kidneys.

Half-Life: Quinapril:0.8 hrQuinaprilat: 3 hr ( in renal impairment).

Time/Action Profile

(effect on BP—single dose)
ROUTEONSETPEAKDURATION
POwithin 1 hr2–4 hrup to 24 hr

Full effects may not be noted for several wk.



Patient/Family Teaching

Pronunciation

KWIN-a-pril